Teacher forced out because she has Hodgkins Lymphoma

A horrible story out of Loudoun, Virginia not far from Washington, DC. Seventh-grade English teacher Alison Yowell has been forced from her job because she ran out of sick days while being treated for relapsed Hodgkin's Lymphoma.



She said the school system forced her to resign when her request for 4 months of unpaid leave for Hodgkin's medical treatment was denied.



The Washington Post reports school system policy mandates that employees complete 90 days of work before they're eligible for unpaid leave. Yowell was hired in August. Yowell's case draws attention to personnel policies in a school district that often struggles to recruit enough qualified teachers in the nation's fastest-growing county!



Superintendent Edgar Hatrick said teachers can't teach if they're not in the classroom. He also said people in Yowell's position could be rehired. How insensitive!



If you would like to write to the board, you can find their e-mail addresses at the Loudoun County School Board site.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap